This decision unit has expertise in working at the interface of chemistry and biology, addressing problems pertaining to development of new technologies, materials and basic understanding in gene editing, gene therapy and gene delivery. The unit combines wet lab experimentation with simulation studies on biomolecular interactions, bridging fundamental science with translational outcomes.

Advancing gene therapies for muscular dystrophy requires innovative approaches for mRNA and RNP complex delivery, along with efficient gene editing strategies. A key challenge is ensuring targeted and effective delivery to muscle cells, which necessitates the development of optimised drug and gene delivery systems — involving novel biomaterial-based carriers and tissue-specific targeting strategies to enhance cellular uptake, stability, and gene correction efficiency.

Understanding RNA–lipid and RNA–protein interactions is central to improving delivery modalities and identifying therapeutic targets. The interaction of RNA with lipid nanoparticles influences stability, encapsulation, and endosomal escape. Additionally, RNA secondary structures and their interactions with proteins play a significant role in gene regulation and drug targeting.